Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

A Phase I/II Trial Combining High-Dose Lenalidomide with Melphalan and Autologous Transplant for Multiple Myeloma: A Report of the Phase I Dose-Finding Study.

Attaya Suvannasankha, MD, Sherif Farag, MD, PhD, FRACP, FRCPA, Rebecca Silbermann, M.D., Robin Obryant, RN, Lisa l Wood, RN, Abigail Huljak, Angie Secrest, Colin D. Crean, Rafat Abonour, MD

Blood (2012) 120 (21): 3146.

https://doi.org/10.1182/blood.V120.21.3146.3146

Published: 2012

Journal Articles

Assessment of Free Light Chains in the Ascites and Pleural Effusion in Patients with Multiple Myeloma: A Report of 2 Cases

Sawsan Rashdan, MD, Sherif Farag, MD, PhD, FRACP, FRCPA, Rafat Abonour, MD, Attaya Suvannasankha, MD

Blood (2011) 118 (21): 5078.

https://doi.org/10.1182/blood.V118.21.5078.5078

Published: 2011

Journal Articles

A Potential Biomarker Panel of Multiple Myeloma Identified Using Label-Free Mass Spectrometry-Based Quantitative Proteomics

Attaya Suvannasankha, MD, Colin D. Crean, Heather M. Sahm, Rafat Abonour, MD, Sherif Farag, MD, PhD, FRACP, FRCPA, Mu Wang, PhD

Blood (2011) 118 (21): 2890.

https://doi.org/10.1182/blood.V118.21.2890.2890

Published: 2011

Journal Articles

The Outcome of the Combination of Tacrolimus, Sirolimus, and ATG for GvHD Prophylaxis on Allogeneic Stem Cell Transplantation From Matched Unrelated Donors

Yaser Homsi, MD, Dareen Alwan, MD, Patrick Kiel, PharmD, Lindsay Rosenbeck, PharnD, Srivastava Shivani, MD, Jennifer E. Schwartz, MD, FRCP(C), Robert P. Nelson, Jr., MD, Rafat Abonour, MD, Michael Robertson, MD, Sherif Farag, MD, PhD, FRACP, FRCPA

Blood (2010) 116 (21): 2345.

https://doi.org/10.1182/blood.V116.21.2345.2345

Published: 2010

Journal Articles

IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody for Multiple Myeloma: Interm Phase 1 Trial Results and Correlative Biologic and Safety Data

Don M Benson, Jr, MD, Courtney E Bakan, Swaminathan Padmanaban, Rafat Abonour, MD, Attaya Suvannasankha, Sundar Jagannath, Ajai Chari, MD, David Clever, Chidimma Kalu, Shauna Collins, Yousef Alghothani, Craig C. Hofmeister, MD, Yvonne Efebera, MD, Stephane Blanchet, Michael A. Caligiuri, MD, Sherif Farag, MD, PhD, FRACP, FRCPA

Blood (2010) 116 (21): 1966.

https://doi.org/10.1182/blood.V116.21.1966.1966

Published: 2010

Journal Articles

Phase 2 Clinical Trial of Oral Lenalidomide, Cyclophosphamide, and Prednisone (RCP) for Newly Diagnosed Multiple Myeloma Patients

Attaya Suvannasankha, Sherif Farag, MD, PhD, FRACP, FRCPA, Robin Obryant, RN, Lisa l Wood, RN, Nicole Porter, Rafat Abonour, MD

Blood (2010) 116 (21): 1970.

https://doi.org/10.1182/blood.V116.21.1970.1970

Published: 2010

Journal Articles

Phase I Trial of Flavopiridol In Relapsed Myeloma: Brief Response In t(4;14) with Significant Neutropenia

Craig C. Hofmeister, MD, Mindy A Bowers, BS, Seungsoo Lee, MS, Mitch A. Phelps, PhD, Don M Benson, Jr, MD, PhD, Eric H. Kraut, MD, William J Hicks, MD, Deidre Deam, RN, Amy J Johnson, PhD, Sherif Farag, MD, PhD, FRACP, FRCPA, Jeffrey A. Jones, MD, MPH, John C. Byrd, MD

Blood (2010) 116 (21): 1933.

https://doi.org/10.1182/blood.V116.21.1933.1933

Published: 2010

Journal Articles

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Alter the Hematopoietic Niche and Treatment In Healthy Volunteers Results In Mobilization of CD34 + Cells, Hematopoietic Colony Forming Cells, and Endothelial Colony Forming Cells

Jonathan Hoggatt, PhD, Brahmananda Reddy Chitteti, PhD, Vani Krishna, Ph.D., Sherif Farag, MD, PhD, FRACP, FRCPA, Magdalena Czader, MD, Mervin C. Yoder, MD, Edward Srour, PhD, Louis M. Pelus, PhD

Blood (2010) 116 (21): 556.

https://doi.org/10.1182/blood.V116.21.556.556

Published: 2010

Journal Articles

Assessment of the Performance of Serum Heavy Chains Immunoassay to Monitor Response to Treatment and Its Correlation with Other Tumor Measurements In Serial Samples From Patients with Newly Diagnosed MM

Attaya Suvannasankha, MD, Sherif Farag, MD, PhD, FRACP, FRCPA, Stephen Harding, PhD, Brian GM Durie, MD, Rafat Abonour, MD

Blood (2010) 116 (21): 2986.

https://doi.org/10.1182/blood.V116.21.2986.2986

Published: 2010

NARROW

A Phase I/II Trial Combining High-Dose Lenalidomide with Melphalan and Autologous Transplant for Multiple Myeloma: A Report of the Phase I Dose-Finding Study.

Assessment of Free Light Chains in the Ascites and Pleural Effusion in Patients with Multiple Myeloma: A Report of 2 Cases

A Potential Biomarker Panel of Multiple Myeloma Identified Using Label-Free Mass Spectrometry-Based Quantitative Proteomics

The Outcome of the Combination of Tacrolimus, Sirolimus, and ATG for GvHD Prophylaxis on Allogeneic Stem Cell Transplantation From Matched Unrelated Donors

IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody for Multiple Myeloma: Interm Phase 1 Trial Results and Correlative Biologic and Safety Data

Phase 2 Clinical Trial of Oral Lenalidomide, Cyclophosphamide, and Prednisone (RCP) for Newly Diagnosed Multiple Myeloma Patients

Phase I Trial of Flavopiridol In Relapsed Myeloma: Brief Response In t(4;14) with Significant Neutropenia

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Alter the Hematopoietic Niche and Treatment In Healthy Volunteers Results In Mobilization of CD34 + Cells, Hematopoietic Colony Forming Cells, and Endothelial Colony Forming Cells

Assessment of the Performance of Serum Heavy Chains Immunoassay to Monitor Response to Treatment and Its Correlation with Other Tumor Measurements In Serial Samples From Patients with Newly Diagnosed MM

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only